ArticleCellular oncology (Dordrecht, Netherlands)2016
WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report.
Article in Cellular oncology (Dordrecht, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Treatment challenges in glioblastoma: a case report.Frontiers in oncology · 2025Article
- DNA hypermethylation ofEpigenetics · 2022Article
- Article
- Upper aerodigestive tract carcinoma: Development of a (epi)genomic predictive model for recurrence and metastasis.Oncology letters · 2020Article
- Epigenetic Alterations Associated with the Overall Survival and Recurrence Free Survival among Oral Squamous Cell Carcinoma Patients.Journal of clinical medicine · 2020Article
- Iodine‑131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma.International journal of oncology · 2020Article
- (Cyto)genomic and epigenetic characterization of BICR 10 cell line and three new established primary human head and neck squamous cell carcinoma cultures.Genes & genomics · 2019Article
- Cytogenetics and Cytogenomics Evaluation in Cancer.International journal of molecular sciences · 2019Review
- Article
- Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Head and neck cancer: searching for genomic and epigenetic biomarkers in body fluids - the state of art.Molecular cytogenetics · 2019Review
- Role of β-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2018Article
- Article
- Genomic and epigenetic signatures associated with survival rate in oral squamous cell carcinoma patients.Journal of Cancer · 2018Article
- Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients.Scientific reports · 2017Article
- CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma - a short report.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Genetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor.Molecular cytogenetics · 2017Article
- Early detection and personalized treatment in oral cancer: the impact of omics approaches.Molecular cytogenetics · 2016Review
- Proteomics-based Predictive Model for the Early Detection of Metastasis and Recurrence in Head and Neck Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOral squamous cell carcinoma (OSCC) is a frequently occurring aggressive malignancy with a heterogeneous clinical behavior. Based on the paucity of specific early diagnostic and prognostic biomarkers, which hampers the appropriate treatment and, ultimately the development of novel targeted therapies, we aimed at identifying such biomarkers through a genetic and epigenetic analysis of these tumors.
methods93 primary OSCCs were subjected to DNA copy number alteration (CNA) and methylation status analyses using methylation-specific multiplex ligation-dependent probe amplification (MS-MPLA). The genetic and epigenetic OSCC profiles obtained were associated with the patients' clinic-pathological features.
resultsWe found that WT1 gene promoter methylation is a predictor of a better prognosis and that MSH6 and GATA5 gene promoter methylation serve as predictors of a worse prognosis. GATA5 gene promoter methylation was found to be significantly associated with a shorter survival rate. In addition, we found that PAX5 gene promoter methylation was significantly associated with tongue tumors. To the best of our knowledge, this is the first study that highlights this specific set of genes as epigenetic diagnostic and prognostic biomarkers in OSCC.
conclusionsOur data highlight the importance of epigenetically assessing OSCCs to identify key genes that may serve as diagnostic and prognostic biomarkers and, potentially, as candidate therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.